News

Madison Air Solutions (NYSE:MAIR) reported first-quarter 2026 results in its first earnings call as a public company, highlighting double-digit pro forma sales and earnings growth, strong

• This Underrated Natural Gas Stock Could Rally Double-Digits Soon

Natural Gas Services Group (NYSE:NGS) reported a record first quarter, with management citing higher utilization, large-horsepower

• 3 Stocks Poised to Grow on European Rearmament Spending

Karman (NYSE:KRMN) reported record fiscal first-quarter results and raised its full-year outlook, citing broad-based growth across its legacy

Kayne Anderson BDC (NYSE:KBDC) reported first-quarter 2026 net investment income of $0.43 per share, covering its $0.40 quarterly dividend by 108%, as management emphasized the company’s defensive

Janus International Group (NYSE:JBI) reported first-quarter results that topped management’s internal expectations despite what executives described as a still-challenging macroeconomic backdrop

GCT Semiconductor (NYSE:GCTS) reported higher first-quarter revenue and said its 5G chipset commercialization efforts continued to gain traction, with management pointing to increased shipments

• High-yield, low-beta value plays for buy-and-hold investors

B&G Foods (NYSE:BGS) reported a first-quarter loss as divestiture-related charges weighed on results, while management said the company

Andersen Group (NYSE:ANDG) reported first-quarter 2026 revenue and adjusted EBITDA above its prior guidance, with management pointing to broad-based organic growth across tax service lines, higher

Astrana Health (NASDAQ:ASTH) CEO and President Brandon Sim said the value-based care company is seeing early benefits from its acquisition of Prospect, while reporting stronger-than-expected

a.k.a. Brands (NYSE:AKA) reported a stronger-than-expected start to fiscal 2026, with first-quarter net sales rising 3% to $132.5 million and Adjusted EBITDA increasing to $5.1 million, management

Verrica Pharmaceuticals (NASDAQ:VRCA) reported higher first-quarter revenue and record demand for its molluscum contagiosum treatment YCANTH, while outlining progress on late-stage development

Upexi (NASDAQ:UPXI) reported higher fiscal third-quarter revenue but a large net loss tied primarily to unrealized losses on its Solana holdings, as management said a weak crypto market weighed on

TriSalus Life Sciences (NASDAQ:TLSI) reported slightly lower first-quarter revenue and reduced its full-year 2026 revenue outlook, citing disruption from a broad commercial reorganization and a

Relmada Therapeutics (NASDAQ:RLMD) said it remains on track to begin its Phase 3 RESCUE registrational program for NDV-01 in mid-2026 after reporting 12-month Phase 2 data in non-muscle invasive

QuickLogic (NASDAQ:QUIK) reported higher first-quarter fiscal 2026 revenue and reiterated expectations for strong full-year growth, as management highlighted progress in radiation-hardened FPGA

Paysign (NASDAQ:PAYS) reported what executives described as the strongest start to a year in the company’s history, with first-quarter 2026 revenue rising 50.8% year over year to $28 million and

OptimizeRx (NASDAQ:OPRX) reported first-quarter fiscal 2026 results that topped consensus expectations, while management lowered its full-year revenue outlook, citing continued caution among life

• 3 Clean Energy Stocks With Bullish Moving Average Signals

Nextpower (NASDAQ:NXT) reported a strong finish to fiscal 2026, with executives pointing to record backlog, growth in its core solar

NeuroPace (NASDAQ:NPCE) raised its 2026 revenue outlook after reporting first-quarter results that management said reflected continued demand for its RNS System and improving commercial execution

Nyxoah (NASDAQ:NYXH) reported 13% sequential worldwide net revenue growth in the first quarter of 2026, driven primarily by continued adoption of its Genio system in the United States, where the

National CineMedia (NASDAQ:NCMI) reported first-quarter 2026 results that management said were in line with expectations, as the cinema advertising company faced typical seasonal weakness

• MaxCyte: Building the Future of Cell and Gene Therapy Innovation

MaxCyte (NASDAQ:MXCT) reported lower first-quarter revenue compared with the prior year, as management said discontinued SPL

Spectral AI (NASDAQ:MDAI) said it remains on track toward potential U.S. regulatory clearance and commercialization of its DeepView system for burn assessment, while reporting lower first-quarter

Lumexa Imaging (NASDAQ:LMRI) reported first-quarter results that management said were in line with expectations, as growth in advanced imaging modalities helped offset seasonal volume pressure and

• Is Kintara Therapeutics A Hidden Gem?

Kura Oncology (NASDAQ:KURA) reported $5.8 million in first-quarter net product revenue from KOMZIFTI, its first commercial product, and said the launch is